Trial Profile
Randomized, Dose-finding Study of BF 2.649 5 [BF-2649, tiprolisant], 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Pitolisant (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 12 Aug 2009 Actual patient number (108) added as reported by ClinicalTrials.gov.
- 12 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.